Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Nathalie OLYMPIOS

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

N. OLYMPIOS1, M. Lambertini2, C. Calbrix3, M. Saint-Ghislain1, M. Fontanilles1, A. Loeb4, M. Leheurteur1, I. Demeestere5, F. Di Fiore1, A. Perdrix6, F. Clatot1

Author affiliations

  • 1 Medical Oncology, Centre Henri Becquerel, 76038 - Rouen/FR
  • 2 Department Of Medecine, Institute Jules Bordet, 1000 - Brussels/BE
  • 3 Biopathology, Centre Henri Becquerel, 76038 - Rouen/FR
  • 4 Medical Information Department, Centre Henri Becquerel, 76038 - Rouen/FR
  • 5 Fertility Clinic, Hopital Erasme, 1070 - Brussels/BE
  • 6 Biopathology, Centre Henri Becquerel, 76000 - Rouen/FR
More

Resources

Abstract 2916

Background

AMH is a promising biomarker of treatment-induced gonadal damage. The impact of carrying a deleterious germline BRCA mutation, adding a taxane to anthracycline-based CT and using adjuvant ET on gonadal function following CT remains unclear. We assessed the influence of these 3 factors on AMH levels before and after adjuvant CT in EBC patients.

Methods

This monocentric retrospective study included consecutive EBC patients aged ≤40 years treated with adjuvant FEC CT between 2008 and 2016, known germline BRCA status and available frozen plasma samples before and after CT. AMH levels (ng/mL) were assessed before starting CT, 1 year and over 3 year after diagnosis.

Results

148 patients were included. 35 (24%) patients harbored a deleterious germline BRCA mutation, 127 (86%) received a taxane following FEC CT and 90 (61%) had adjuvant ET after CT. Overall median age was 35 (range 22-40). In the whole cohort, median AMH levels dropped after adjuvant CT (from 1.69 to 0.06, p < 0.0001) and slightly recovered after 3 years (0.17, p < 0.0001). No difference in baseline (1.94 vs 1.66, p = 0.53), 1-year (0.09 vs 0.06, p = 0.39) or 3-year (0.25 vs 0.16, p = 0.43) AMH levels was observed between patients with or without a BRCA mutation. Significant lower AMH levels were observed for patients who received a FEC-taxane regimen as compared to those treated with FEC only CT 1 year after diagnosis (0.04 vs 0.22, p = 0.0006), with no difference at 3 years (0.18 vs 0.06, p = 0.47). Patients treated with adjuvant ET had slightly higher AMH levels than those who did not receive ET 1 year after diagnosis (0.12 vs 0.02, p = 0.008) with no difference at 3 years (0.11 vs 0.20, p = 0.22).

Conclusions

Use of adjuvant CT is associated with a significant and durable alteration in ovarian reserve measured by AMH levels. Addition of taxanes to FEC increased CT-induced gonadotoxicity immediately after CT exposure but not at longer follow-up. Carrying a germline BRCA mutation and using adjuvant ET following CT were not associated with additional negative impact on patients’ ovarian reserve after treatment.

Clinical trial identification

Legal entity responsible for the study

Centre Henri Becquerel, Rouen, France.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings